16,540 Shares in Novo Nordisk A/S $NVO Purchased by Mengis Capital Management Inc.

Mengis Capital Management Inc. acquired a new stake in Novo Nordisk A/S (NYSE:NVO) during the third quarter, Holdings Channel reports. The firm acquired 16,540 shares of the company’s stock, valued at approximately $918,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. SG Americas Securities LLC increased its stake in shares of Novo Nordisk A/S by 2,101.5% in the third quarter. SG Americas Securities LLC now owns 2,383,176 shares of the company’s stock worth $132,242,000 after purchasing an additional 2,274,925 shares in the last quarter. DAVENPORT & Co LLC boosted its holdings in Novo Nordisk A/S by 54.8% in the 3rd quarter. DAVENPORT & Co LLC now owns 2,642,498 shares of the company’s stock worth $146,644,000 after buying an additional 935,468 shares during the period. Sustainable Growth Advisers LP boosted its holdings in Novo Nordisk A/S by 11.7% in the 2nd quarter. Sustainable Growth Advisers LP now owns 6,192,636 shares of the company’s stock worth $427,416,000 after buying an additional 649,390 shares during the period. Baird Financial Group Inc. grew its stake in Novo Nordisk A/S by 42.6% in the 2nd quarter. Baird Financial Group Inc. now owns 1,476,673 shares of the company’s stock valued at $101,920,000 after buying an additional 441,034 shares in the last quarter. Finally, Holocene Advisors LP bought a new stake in Novo Nordisk A/S during the 2nd quarter valued at $25,745,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

NYSE:NVO opened at $38.51 on Thursday. Novo Nordisk A/S has a 52-week low of $35.85 and a 52-week high of $91.90. The stock has a fifty day moving average of $51.96 and a 200 day moving average of $52.58. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. The firm has a market capitalization of $171.95 billion, a price-to-earnings ratio of 11.10 and a beta of 0.73.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.11. The firm had revenue of $12.43 billion for the quarter, compared to analysts’ expectations of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. On average, research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The business also recently announced a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be paid a $1.2751 dividend. This represents a yield of 541.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 23.63%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on NVO shares. TD Cowen reaffirmed a “buy” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 3rd. BMO Capital Markets reissued a “market perform” rating on shares of Novo Nordisk A/S in a report on Thursday, February 5th. Deutsche Bank Aktiengesellschaft downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, February 23rd. HSBC reaffirmed a “hold” rating and set a $54.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, December 10th. Finally, Jefferies Financial Group raised shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a report on Thursday, February 12th. Five analysts have rated the stock with a Buy rating, seventeen have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Novo Nordisk A/S has an average rating of “Hold” and an average price target of $53.93.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Morgan Stanley upgraded NVO to Equal‑weight and set a $40 price target, citing that the recent sell‑off has better priced in mid‑term risks — a catalyst for short‑term buying. Morgan Stanley upgrade
• Positive Sentiment: Novo announced significant capacity investments: a $372.5M expansion in Monksland, Athlone (Ireland) and a €432M upgrade to produce oral Wegovy — signals of management backing long‑term growth in obesity/GLP‑1. Monksland expansion Ireland facility upgrade
• Neutral Sentiment: Goldman Sachs reaffirmed a Neutral rating on NVO — supportive of no dramatic re‑rating but not a bullish endorsement. Goldman Sachs reaffirms Neutral
• Negative Sentiment: The U.S. FDA sent Novo a second warning letter ordering it to stop a consumer Ozempic ad, saying the commercial makes false or misleading claims — raises regulatory scrutiny and potential marketing limitations for a core franchise. Reuters: FDA warning
• Negative Sentiment: Industry groups (AHA) are urging HRSA to block Novo’s new claims‑data submission policy affecting 340B hospitals — potential policy & reimbursement friction that could pressure margins or access. AHA on 340B policy
• Negative Sentiment: Investor litigation risk surfaced as Pomerantz LLP opened an investigation into Novo Nordisk investors — a potential headwind if suits follow regulatory or disclosure claims. Pomerantz investor investigation
• Negative Sentiment: Novo said it will halve the U.S. list price of Wegovy in 2027 — direct pricing pressure on a growth driver that may weigh on revenue expectations. Wegovy price cut
• Negative Sentiment: Competitive and generic threats: Aspen expects a Canada nod for a generic Ozempic this year and Roche is publicly targeting share gains in weight‑loss — potential market share and pricing headwinds. Aspen generic Ozempic Roche competition

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.